The biology and management of non-small cell lung cancer

Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.

[1]  S. Temin,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2016, Journal of oncology practice / American Society of Clinical Oncology.

[2]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[3]  Thomas J. Smith,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[5]  B. Taylor,et al.  A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. , 2017, Cancer discovery.

[6]  Haikuo Zhang,et al.  Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors , 2016 .

[7]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Cai,et al.  A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients. , 2019, Annals of translational medicine.

[9]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[10]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[11]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[12]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[13]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[14]  F. Q. Ribeiro The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[15]  Guoping Cai,et al.  Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. , 2017, Cancer discovery.

[16]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[18]  S. Novello,et al.  Lung cancer in never smokers: a different disease , 2014, Current Respiratory Care Reports.

[19]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Stossi,et al.  Mutual Regulation of Tumour Vessel Normalization and Immunostimulatory Reprogramming , 2017, Nature.

[21]  David Wholley,et al.  Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 , 2015, Clinical Cancer Research.

[22]  Jeanne Shen,et al.  Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[23]  Mari Mino-Kenudson,et al.  Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.

[24]  G. Rossi,et al.  Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. , 2017, Cancer treatment reviews.

[25]  K. O'Byrne,et al.  Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[27]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Ying Cheng,et al.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[29]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[30]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[31]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[32]  J. Schlessinger,et al.  The EGFR family: not so prototypical receptor tyrosine kinases. , 2014, Cold Spring Harbor perspectives in biology.

[33]  L. Galluzzi,et al.  Combinatorial Strategies for the Induction of Immunogenic Cell Death , 2015, Front. Immunol..

[34]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[35]  L. Sequist,et al.  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. , 2016, The Lancet. Oncology.

[36]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[37]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[38]  Jing Wang,et al.  STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. , 2016, Cancer research.

[39]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[40]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[41]  J. Wolchok,et al.  Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 , 2013, The Journal of experimental medicine.

[42]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  R. West,et al.  Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users , 2017, Annals of Internal Medicine.

[44]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[45]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.

[46]  Gideon Blumenthal,et al.  FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy , 2016, The oncologist.

[47]  Antonio Marchetti,et al.  Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Nicole Benoit,et al.  p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. , 2003, Journal of the National Cancer Institute.

[49]  K. Rabe,et al.  Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. , 2017, The New England journal of medicine.

[50]  Serafino Pantano,et al.  First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study , 2017, The Lancet.

[51]  M. Socinski,et al.  Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer , 2015, The Lancet. Oncology.

[52]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[53]  F. Clavel-Chapelon,et al.  Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study , 2005, BMJ : British Medical Journal.

[54]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[55]  Walter J Curran,et al.  Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.

[56]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[57]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[58]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[59]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[60]  P. Bunn,et al.  Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer , 2013, PloS one.

[61]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[62]  Robert J. Lonigro,et al.  Integrative Clinical Genomics of Metastatic Cancer , 2017, Nature.

[63]  Jennifer A. Hobin,et al.  Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology , 2015, Clinical Cancer Research.

[64]  Yu Cao,et al.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.

[65]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[66]  F. Cappuzzo,et al.  Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[67]  J. Blay,et al.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.

[68]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[69]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[70]  Benjamin Movsas,et al.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. , 2011, Journal of the National Cancer Institute.

[71]  Tae Min Kim,et al.  An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer , 2016 .

[72]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[73]  M. Ahn,et al.  Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[75]  A. Gemma,et al.  F1000 highlights , 2010 .

[76]  P. Jänne,et al.  MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[78]  L. Zitvogel,et al.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. , 2013, Immunity.

[79]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[80]  M. Kris,et al.  Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[82]  W. Pao,et al.  Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.

[83]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[84]  Yasushi Okuno,et al.  Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer , 2017, Nature Communications.

[85]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[86]  C. Paweletz,et al.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  A. Shaw,et al.  Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial , 2017, The Lancet. Oncology.

[88]  D. Carbone,et al.  First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer , 2017 .

[89]  Tae Min Kim,et al.  Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[90]  Z. Liao,et al.  Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[91]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[92]  Young Hak Kim,et al.  Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial , 2017, The Lancet.

[93]  W. Liang,et al.  Robotic Versus Video-assisted Lobectomy/Segmentectomy for Lung Cancer: A Meta-analysis , 2017, Annals of surgery.

[94]  E. Chiocca,et al.  Oncolytic Viruses in Cancer Treatment: A Review , 2017, JAMA oncology.

[95]  Edward S. Kim,et al.  Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[97]  L. Sequist,et al.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.

[98]  N J Wald,et al.  The accumulated evidence on lung cancer and environmental tobacco smoke , 1997, BMJ.

[99]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[100]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[101]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[102]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[103]  A. Shaw,et al.  Targeting ALK: Precision Medicine Takes on Drug Resistance. , 2017, Cancer discovery.

[104]  Anthony J Alberg,et al.  Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[105]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[106]  R. Govindan,et al.  Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[107]  Ashwini Naik,et al.  Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.

[108]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[109]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[110]  Ross Camidge,et al.  Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[112]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[113]  Francisco J. Sánchez-Rivera,et al.  Keap1 loss promotes Kras-driven lung cancer and results in a dependence on glutaminolysis , 2017, Nature Medicine.

[114]  Pedagógia,et al.  Cross Sectional Study , 2019 .

[115]  Jeffrey W. Clark,et al.  Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer , 2014 .

[116]  R. Herbst,et al.  Diminished but not dead: chemotherapy for the treatment of NSCLC. , 2016, The Lancet. Oncology.

[117]  K. Propert,et al.  A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. , 1990, The New England journal of medicine.

[118]  J. Ebbert,et al.  Varenicline for tobacco dependence. , 2008, The New England journal of medicine.

[119]  C. Schumann,et al.  Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. , 2015, The Lancet. Oncology.

[120]  Masahiro Fukuoka,et al.  Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[122]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[123]  L. Sequist,et al.  The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies , 2015, Clinical Cancer Research.

[124]  N. Mitsiades,et al.  Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. , 1999, The Journal of clinical endocrinology and metabolism.

[125]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[126]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[127]  David M. Hyman,et al.  The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. , 2017 .

[128]  S. Gettinger,et al.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.

[129]  P. Harari,et al.  Understanding resistance to EGFR inhibitors—impact on future treatment strategies , 2010, Nature Reviews Clinical Oncology.

[130]  W. Coley The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .

[131]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .

[132]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[133]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[134]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[135]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[136]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[137]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[138]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  M. Fukuoka,et al.  Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. , 2007, Cancer research.

[140]  Maximilian Diehn,et al.  Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers , 2017, Nature Genetics.

[141]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[142]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[143]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[144]  M. Ladanyi,et al.  A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers , 2016, The Lancet. Oncology.

[145]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[146]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[147]  E. Tartour,et al.  Control of the Immune Response by Pro-Angiogenic Factors , 2014, Front. Oncol..

[148]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[149]  Steven E Schild,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[150]  S. Peters,et al.  Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[152]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.